A study in the Journal of the American Pharmacists Association found that patients with type 2 diabetes taking captopril had a significantly higher risk of suffering from pulmonary adverse drug effects, compared with those taking other angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. The researchers said the study highlights the importance of considering a medication's adverse event profile and how they may affect pulmonary function in infections such as COVID-19.
Captopril linked to adverse pulmonary events in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.